Januvia 100 mg film-coated tablets
Authorisation EU/1/07/383/13-18 · Merck Sharp & Dohme BV
- Licence holder
- Merck Sharp & Dohme BV (all products →)
- Active substance
- Sitagliptin phosphate monohydrate
- Clinical trials
- 9 clinical trials →
- Dosage form
- Film-coated tablet
- Route of administration
- Oral use
- ATC codes
- A10BH, A10BH01
- First authorised
- 21/03/2007
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Sitagliptin phosphate monohydrate: supply and approvals
60 authorised products on the HPRA list contain Sitagliptin phosphate monohydrate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 383. It has been authorised for 19 years (since 21 March 2007). The HPRA list does not say whether it is on sale.
Other medicines with Sitagliptin phosphate monohydrate in Ireland
7 other products on the HPRA list contain Sitagliptin phosphate monohydrate, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Januvia 25 mg film-coated tablets | Merck Sharp & Dohme BV, | Centralised EU authorisation | Not stated |
| Januvia 50 mg film-coated tablets | Merck Sharp & Dohme BV | Centralised EU authorisation | Not stated |
| Steglujan 15 mg/100 mg film-coated tablets | Merck Sharp & Dohme BV | Centralised EU authorisation | Not stated |
| Steglujan 5 mg/100 mg film-coated tablets | Merck Sharp & Dohme BV | Centralised EU authorisation | Not stated |
| Xelevia 100 mg film-coated tablets | Merck Sharp & Dohme BV | Centralised EU authorisation | Not stated |
| Xelevia 25 mg film-coated tablets | Merck Sharp & Dohme BV | Centralised EU authorisation | Not stated |
| Xelevia 50 mg film-coated tablets | Merck Sharp & Dohme BV | Centralised EU authorisation | Not stated |
Other substances in ATC group A10BH
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 7 other active substances share the group A10BH with this product:
Sitagliptin as monohydrate phosphate salt (3) · Vildagliptin (2) · Saxaglitpin (1) · Saxagliptin (1) · Sitagliptin (1) · Linagliptin (1) · Alogliptin (as benzoate) (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Merck Sharp & Dohme BV holds 34 products on the HPRA list, with 12 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.